An observational study in Cerebral Palsy, Infant Development and Development, Infant, sponsored by Danish Research Centre for Magnetic Resonance. Recruiting at 1 site in Denmark. Open to participants aged 2 Months to 11 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-28.
Sponsored by Danish Research Centre for Magnetic Resonance · Observational
Background: Early diagnosis of cerebral palsy (CP) is crucial, enabling intervention when neuroplasticity is at its highest. Magnetic resonance imaging (MRI) plays a vital role in CP diagnosis. Currently, diagnostic MRI of newborns and infants with suspected brain damage relies heavily on structural MR images. The current study aims to i) establish procedures for clinical infant and toddler MRI during natural sleep, ii) use advanced MRI sequences, such as advanced diffusion-weighted imaging (DWI), that may be more sensitive in detecting early brain damage, and iii) map relationships between early brain development, and motor function and development.
Methods: The NIBS-CP study will enroll approximately 200 infants either at risk for CP or typically developing. Infants will be followed longitudinally (for three waves) between 3 months and 2 years of age with cerebral MRI at 3 Tesla and comprehensive assessments of motor and cognitive functioning. The MRI protocol includes advanced diffusion-weighted imaging, high-resolution structural MRI, and MR spectroscopy. The motor and cognitive assessments include Hand Assessment in Infants, Alberta Infant Motor Scales, Hammersmith Infant Neurological Examination, Peabody Developmental Motor Scales, Bayley Scales of Infant Development, and Ages and Stages Questionnaires. NIBS-CP aims to establish normative material on early brain development of Danish children and conduct normative modeling of typical and atypical development to identify deviations in brain development at the level of the single child.
Discussion: Identifying predictive brain structural features of motor function and motor development is key to the future use of early MRI in the clinical work-up, as this promotes early diagnosis and (clinical) intervention strategies tailored to the individual child.
Diagnostic magnetic resonance imaging (MRI) of newborns and infants with suspected brain damage is today based on conventional structural MR images with the focus on identifying major structural brain pathology. However, advanced MRI sequences, such as advanced diffusion-weighted imaging, may be more sensitive to detecting brain damage. The NeuroImaging of Babies during natural Sleep to assess typical development and CP (NIBS-CP) study is a longitudinal cohort study of infants and toddlers aged 3-24 months, aimed at studying early brain development in infants at risk of cerebral palsy (CP) and typically developing infants using advanced MRI sequences. The NIBS-CP cohort consists of:
Infants at risk for CP, recruited from the Cerebral Palsy: Early Diagnosis and Intervention Trial (CP-EDIT).
The ongoing Danish CP-EDIT by principal investigator Professor Christina Høi-Hansen is registered with ClinicalTrials.gov ID NCT05835674. CP-EDIT will enroll 160 infants aged 3-11 months with CP or high risk of CP. Infants will be followed longitudinally with a large battery of motor, neurological, and cognitive assessments during the first two years of life. In addition, CP-EDIT contains information from patient journals on diagnostic MRI, but CP-EDIT does not include the collection of MRI scans as part of the study. For infants enrolled in CP-EDIT, participation in NIBS-CP only includes advanced MRI scans and parent-reported questionnaires. All neurological, motor, and cognitive assessments will be undertaken in CP-EDIT.
AIMS
The NIBS-CP project aims to:
Initiate a cohort of typically developing infants and toddlers, and perform longitudinal advanced MRI of infants at high risk for CP. The NIBS-CP cohort will be used to:
HYPOTHESES
The primary hypotheses are that:
The secondary hypotheses are that:
Reduced hand functioning and hand functioning asymmetry will also be related to:
Furthermore, the normative modeling framework, similar to pediatric growth curves, will be used to elucidate how individual infants with high risk for CP deviate from the norm on different brain outcome measures. The relationships between developing motor functioning and brain structural outcome measures will also be mapped, as little is known about how individual differences in hand and motor functions of the clinically used assessments with the brain outcome measures. Elucidating brain outcome measures that relate to developing motor functions is crucial for using early MRI scans in medical evaluations. Such patterns could help predict a child's motor skills and how these might develop, which could be important for directing future interventions.
METHODS
The following methods will be used for the NIBS-CP study:
Magnetic Resonance Imaging (MRI) The MRI protocol consists of several different structural MRI sequences, diffusion-weighted imaging, and MR-spectroscopy. Children will be scanned using a 3 Tesla MR scanner. The MRI protocol takes approximately 45 minutes. If the infant/toddler moves during a specific sequence, the specific sequence will be redone, if possible. In such cases, the protocol may take up to 1 hour. Earplugs as well as headphones will help minimize the scanner-related noise experienced by the infant/toddler.
Structural magnetic resonance imaging (sMRI) gives high-resolution images of the brain anatomy with different contrasts (e.g., T1-weighted and T2-weighted images). This kind of scanning allows for the quantification of different brain measures, such as volumes of specific brain regions and cortical thickness estimates. Moreover, sMRI provides the images that the neuroradiologist will read and use diagnostically.
Diffusion-weighted imaging (DWI) provides information about the microstructure of both gray and white matter tissue as well as structural connectivity.
Proton MR spectroscopy (MRS) will yield a metabolic profile of the basal ganglia/internal capsule region, including markers of neuronal integrity (e.g., N-acetyl-aspartate and glutamate), and glial markers (e.g., myoinositol). Voxels will include the left or right basal ganglia and internal capsule, to capture the metabolic profile in this region.
Sequences will be ordered so that the most important sequences (sMRI > DWI > MRS) will be acquired first, to optimize the chances of getting the sequences needed for diagnostic purposes for the infants at high risk of CP needing a diagnostic scan.
Neurological assessments Hammersmith Infant Neurological Examination (HINE) will be conducted by a pediatrician at Hvidovre Hospital for the typically developing infants and within the CP-EDIT study for the infants at risk for CP.
Motor and cognitive assessments
Motor and cognitive assessments of the typically developing infants will be conducted by physio- and occupational therapists at Hvidovre Hospital. Infants at risk for CP will undergo the same tests within the CP-EDIT protocol. The following motor and cognitive tests are included:
Questionnaires
Neuropsychological data will be collected using the following parent-reported questionnaires for all participants (typically developing and at-risk for CP):
STUDY OUTLINE
Study outline for the typically developing infants in NIBS-CP:
The NIBS-CP study consists of three assessment rounds:
Study outline for CP-EDIT participants in NIBS-CP:
Families enrolled in CP-EDIT will be asked to participate in three MRI scans at age 2-11 months (Round 1, inclusion), age 12 months (Round 2, first follow-up), and age 24 months (Round 3, second follow-up) in parallel to CP-EDIT. Participation in NIBS-CP only includes MRI scans and parent-reported questionnaires (ASQ and Demographics \& Background).
STATISTICAL CONSIDARATIONS Longitudinal data will be collected from 200 infants. Infant cohorts are typically smaller than adult cohorts, because of the challenges of MR-scanning this age group (Korom et al., 2022). The success rate of the scans is expected to be around 75% for sMRI, 60% for DWI, and 50% for MRS. The decline in success rate is due to the order of the sequences, given the higher risk of infants waking up the longer the scan time.
Statistical analyses will be conducted in statistical software tools, such as R and SPSS, and in image analysis specific tools, such as FreeSurfer and FSL. We will use e.g., analysis of covariance (ANCOVA) and multiple linear regression for cross-sectional data, and e.g., linear mixed models, generalized additive mixed models (GAMM), and repeated measurements analysis of variance (ANOVA) for longitudinal data
CP patient cohorts are biologically and clinically heterogeneous. Thus, in addition to examining differences in group averages, the normative modeling framework will be used (Rutherford et al., 2023, 2022) to quantify heterogeneity in structural brain measures by mapping structural brain changes at the level of the individual. Normative modeling is a leading tool in precision medicine, as it allows for elucidating differences at the individual level, mapped in relation to a reference model of normative data, similar to height growth charting in pediatric medicine. Here, normative modeling involves charting percentiles of variation across a population in terms of mappings of brain measures, or e.g., between brain measures and motor functioning. Publicly available datasets, such as the Healthy Brain and Child Development (HBCD) study, will be used to enhance our training dataset. In all models with MRI, age, sex, and variables estimating subject motion during MRI will be utilized as covariates.
1,936 studies on the registry are indexed under Cerebral Palsy; 458 are open to participants now.
This study's planned enrollment of 200 is above the median of 63 across 472 observational studies indexed under Cerebral Palsy.
Browse Cerebral Palsy studies →Danish Research Centre for Magnetic Resonance is the lead sponsor of 14 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Infants at risk of cerebral palsy:
160 infants with a high risk of CP will be enrolled in CP-EDIT (ClinicalTrials.gov ID NCT05835674). At least 2/3 are expected to be from the 'new-born detectable risk pathway' and less than 1/3 from the 'infant-detectable pathway'. At inclusion, infants will mainly be 3-6 months of age, though the age range between 2-11 months is accepted. It is expected that at least 50-60 of the high-risk infants will participate in the NIBS-CP study, with an upper limit of 100 infants.
Typically developing infants:
To establish a Danish normative sample of early brain development and a control group to the CP-EDIT cohort, approx. 140-150 typically developing infants will be recruited to NIBS-CP (approx. 200 infants when combining the high-risk and typically developing groups). The age range and mean age of the typically developing infants will be matched to that of the high-risk infants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Group: 'Newborn-detectable risk-pathway'
Group: 'Infant detectable risk-pathway'
Additional inclusion criteria for inclusion in NIBS-CP for both CP-risk groups:
- Consent to health-relevant information on clinical findings being passed on to the medical doctors in CP-EDIT and/or their primary care physician.
Inclusion Criteria Typically developing infant population:
Exclusion Criteria (all groups):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Born after gestational week 37, Uneventful birth, No known history of brain injury, No known neurological disorders
Other: No intervention, observational
Recruitment through CP-EDIT (Clinical trials.gov ID: NCT05835674), inclusion criteria. 'Newborn-detectable risk-pathway'. Preterm birth with gestational age below 32 or birth weight below 1500 g and clinical concern, Moderate to severe brain injury (Papile grade 3 to 4 intraventricular haemorrhage, cystic periventricular leukomalacia, neonatal stroke, term hypoxic-ischaemic encephalopathy (≥35 weeks gestation at birth) or other significant neurological condition), History (e.g. neonatal seizures, Extra Corporal Membrane Oxygenation, meningitis, kernicterus, severe hypoglycemia) or neurological risk factors (brain malformation, increased tone), Parental concern and one of the factors above 'Infant detectable risk-pathway'. Inability to sit independently by age 9 months, Hand function asymmetry or crawl asymmetry, Inability to take weight through the plantar surface of the feet, History (as above) or neurological risk factors, Parental concern and one of the factors above.
Other: No intervention, observational
No intervention, observational
Diffusion-weighted magnetic resonance imaging
Microstructural measures obtained from fixel-based and tensor-based analysis.
Time frame: Baseline, 12 months, 24 months
Brain volumetric measures
Total brain volume, cortex volume, and white matter volume, as well as regional grey matter volume of cortical parcels and subcortical grey matter structures measured in mm3
Time frame: Baseline, 12 months, 24 months
Cortical thickness
Global and regional measures of apparent cortical thickness measured in mm
Time frame: Baseline, 12 months, 24 months
Brain connectivity measures
Brain connectivity measures obtained from structural covariance and tractography-based connectivity analyses
Time frame: Baseline, 12 months, 24 months
Indices of myelination
T1/T2 contrast in grey and white matter regions
Time frame: Baseline, 12 months, 24 months
MR-spectroscopy measures
Brain metabolic measures (metabolites: NAA, choline, creatine, myoinositol, lactate) obtained from voxels containing the basal ganglia and thalamus in the left and right hemispheres.
Time frame: Baseline, 12 months, 24 months
Surface area
Global and regional surface area measured in mm2
Time frame: Baseline, 12 months, 24 months
Hand assessment for infants (HAI)
The HAI measures the degree and quality of goal-directed actions performed with each hand separately as well as with both hands together. The HAI is scored on 17 items (12 unimanual and 5 bimanual)
Time frame: Baseline, 12 months
Alberta Infant Motor Scale (AIMS)
The AIMS is an observational assessment scale that measures gross motor maturation in infants from birth through independent walking. The scale consists of 58 items organized into four positions: prone, supine, sitting, and standing. Each item describes three aspects of motor performance - weight-bearing, posture, and antigravity movements.
Time frame: Baseline, 12 months
Peabody Developmental Motor Scales (PDMS-2)
PDMS-2 is an in-depth assessment of gross and fine motor skills of children from birth through 5 years.
Time frame: 24 months
Bayley Scales of Infant and Toddler Development, Fourth Edition (BSID-4)
BSID-4 is a standardized and norm-referenced assessment that measures the cognitive, motor, language, and social-emotional development of infants and toddlers aged 0-3 years.
Time frame: 24 months
Ages & Stages (ASQ)
ASQ is a parent-rated questionnaire for screening young children's developmental milestones between the ages of 1 month to 5½ years. There are two main questionnaires, one assessing motor and cognitive development and one assessing socio-emotional development.
Time frame: 12 months, 24 months
Hammersmith Infant Neurological Examination (HINE)
HINE is a standardized and scorable neurological examination used in the diagnosis of CP up to the age of 24 months. The HINE detects CP with more than 90% accuracy and provides objective information about severity.
Time frame: Baseline, 24 months
Plan to share: Undecided
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Danish Research Centre for Magnetic Resonance